drugset / Trial / NCT02086929

Trazodone Once a Day in Major Depression Disorder

NCT02086929

Phase 3 Completed 364 enrolled Angelini Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.

Timeline

Start
2012-12
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Trazodone Small molecule 300 mg
Comparator Venlafaxine Small molecule 75 mg